Metformin is the standard 1st line treatment of Type 2 Diabetes, a disease which is expected to grow by 50% towards 2030 and affect more than 500 million people. The global market for metformin is expected to grow by four to five percent per annum and Vistin Pharma is attractively positioned to capture part of this growth.
Vistin Pharma offers two different Metformin products
- Metformin HCl (API)
- Metformin DC (Direct Compressible Granulate)
Our Metformin is sold to reputable international pharmaceutical companies.
In addition, we can offer out-licencing of Dossier on Metformin tablets.